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The modulation of protein deacetylase SIRT1 has a vast therapeutic potential in treatment of several
aging-associated diseases. Active regulator of SIRT1 (AROS) is a small endogenous protein which was
originally reported to activate SIRT1 through a direct interaction in cancer cells. We show that the
interaction between the two proteins is weak and does not alter the activity of SIRT1 in non-
cancerous human cells. The results of different in vitro SIRT1 activity assays disclosed AROS as an
inhibitor of SIRT1. The functional relationship between AROS and SIRT1 proved to be dependent
on the biological context and experimental setting.
Structured summary of protein interactions:
SIRT1 physically interacts with AROS by anti bait coimmunoprecipitation (1, 2)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Sirtuins are NAD+-dependent class III histone deacetylases. They
catalyze the deacetylation of acetyllysine residues in multiple
histone- and non-histone protein substrates, resulting in the
production of deacetylated lysine, nicotinamide, and 20-O-acetyl-
ADP-ribose. The seven members of the mammalian sirtuin family
(silent information regulator, SIRT1–7) diverge in their subcellular
localizations and biological functions [1,2]. SIRT1 is a predomi-
nantly nuclear protein which regulates several important biologi-
cal processes, ranging from gene transcription and metabolism to
stress tolerance, inﬂammatory response, and cellular senescence
[3]. Although the histones were the ﬁrst described substrates for
SIRT1, later it was also found to exert its enzymatic activity on a
multitude of other proteins, such as transcription factors and co-
factors (p53 [4], p65/NF-jB [5], FOXOs [6], and PGC-1a [7]), as well
as nuclear receptors (peroxisome proliferator-activated receptor c
(PPAR c) [8], androgen receptor [9], and estrogen receptor [10]).
The biological functions of SIRT1 have triggered interest in the
development of SIRT1 inhibitors and activators [11–15]. These
SIRT1 modulators have been suggested to have therapeutic
potential for several chronic diseases that are more common inthe elderly population, such as type 2 diabetes, cardiovascular
disease, cancer, age-related macular degeneration, and neurode-
generative diseases [1,16–19].
The activity of SIRT1 is regulated at several levels in vivo. Since
the deacetylation reaction requires the presence of NAD+ as a
co-substrate in the catalysis, SIRT1 activity is dependent on the
cellular NAD+:NADH ratio which is directly connected with the
metabolic state of the cell [18]. SIRT1 has a central catalytic core
domain and ﬂanking N- and C-terminal extensions which act as
regulatory regions and are targeted by several post-translational
modiﬁcations [20–24]. SIRT1 can also be regulated through
protein–protein interactions occurring at the N- and C-terminal
regulatory regions or directly at the catalytic domain. An example
of the latter is interaction with DBC1 (Deleted in breast cancer-1)
protein, which inhibits the activity of SIRT1 and promotes p53-
mediated apoptosis [25,26].
Active regulator of SIRT1 (AROS) is the only SIRT1 interaction
partner which has been reported to directly increase its catalytic
activity. AROS is a small nuclear and cytoplasmic protein (142 ami-
no acids) which was originally identiﬁed as ribosomal protein S19
binding protein 1 (RPS19BP1 [27]) and was recently reported to
have a role in ribosomal function [28]. The interaction between
SIRT1 and AROS has been shown to be functional in some cancer
cell lines, and AROS has been found to enhance SIRT1-mediated
deacetylation of p53 and to improve cell survival after DNA
damage [29,30]. Here we present results on the SIRT1/AROS
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of AROS. The results indicate that the functional consequences of
the interaction are dependent on the experimental settings and
on the biological context. Therefore, the role of AROS in modulating
the function of SIRT1 must be judged with caution and has to be
validated with various methods.2. Materials and methods
2.1. Recombinant protein production and cell culture
The human SIRT1 cDNA in pcDNA3 expression vector (contain-
ing a C-terminal Myc tag) was kindly provided by Prof. Tony
Kouzarides (Cambridge, UK). Deletion mutants of SIRT1 were con-
structed by PCR ampliﬁcation and cloning into pcDNA3 expression
vector. The human AROS cDNA in pCMV-SPORT6 expression vector
(RPS19BP1-pCMV-SPORT6) was purchased from ImaGenes.
His-tagged (ag5637; purity 85%) and GST-tagged (ag5560; purity
40%) human AROS proteins were purchased from Proteintech.
Full-length His-tagged SIRT1 enzyme was from Enzo (BML-
SE239). All DNA clones were veriﬁed by sequencing.
HEK293 cells (ATCC) were maintained in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) containing fetal calf serum (10%) and
penicillin/streptomycin (all from Gibco). Human ARPE-19 retinal
pigment epithelial cell line (ATCC) was grown as described earlier
[12]. HEK293 and ARPE-19 cells were transfected with Lipofect-
amine 2000 (Life Technologies) or Turbofect transfection reagent
(Thermo Fisher Scientiﬁc) for 24 h before further treatments.
ARPE-19 cells were seeded to 12-well plates (Nunc) at a density
of 105 cells/well 24 h before the start of the treatments. When indi-
cated, etoposide (Sigma) was added to the cells and incubated for
5 h before harvesting the cells. Control transfections contained the
same amount of empty vectors (mock transfection).
2.2. In silico analysis and AR peptides
SIRT1 and AROS protein sequences were aligned manually with
Discover Studio 3.0 (Accelrys Software) based on the hydrophobic-
ity as well as the charges of the amino acid residues. The regions of
complementary amino acids deﬁning complementary surfaces for
protein–protein interaction were used as templates to design AROS
peptides (AR1–4). Furthermore, possible protein–protein interac-
tion sites of AROS were predicted with two on-line softwares:
cons-PPISP and Predict Protein. Cons-PPISP is a consensus neural
network method for predicting protein–protein interaction sites
(pipe.scs.fsu.edu/ppisp). Predict Protein is an automatic on-line
service for protein database searches and the prediction of aspects
of protein structure and function (www.predictprotein.org). AROS
peptide AR5 was selected based on these studies. The AROS pep-
tides AR1–5 were synthesized by GeneCust and they were >95%
pure.
2.3. Co-immunoprecipitation analysis
Cell lysis and immunoprecipitation were performed with slight
modiﬁcations to a previously published protocol [31]. HEK293 cells
were lysed in RIPA buffer (25 mM Tris–HCl (pH 7.6), 150 mM NaCl,
1% NP-40, 1% Na-deoxycholate, 5 mM EDTA, 0.1% SDS) containing
protease inhibitors (Sigma) followed by centrifugation (30 min,
20000g, +4 C). When present, the competing peptides were
added at this stage to a ﬁnal concentration of 2 lM. Cell lysates
were cleared by preincubation with protein A/G agarose beads
(Santa Cruz) to minimize non-speciﬁc binding of proteins to the
immunoprecipitation matrix. AROS was precipitated with rabbit
RPS19BP1 primary antibody (HPA042874, Sigma) and protein A/Gagarose. SIRT1 was immunoprecipitated with rabbit primary
antibody recognizing the C-terminal domain of SIRT1 (ab13749,
Abcam) and protein A/G agarose. After washing with RIPA buffer,
the precipitates were eluted by boiling and analyzed by Western
blotting.
2.4. Western blotting
For Western blots following co-immunoprecipitation, HEK293
cells were processed as described above. Western blot analyses
of ARPE-19 cell samples were done as previously described [12].
Brieﬂy, the cells were lysed into M-PER Mammalian Protein
Extraction Reagent (Thermo Fisher Scientiﬁc) followed by centrifu-
gation (20 min, 16000g, +4 C). After electrophoretic separation
in SDS–PAGE gel, the proteins were transferred onto Hybond-ECL
nitrocellulose transfer membrane (GE Healthcare) and detected
using speciﬁc antibodies. The following commercially available
primary antibodies were used to detect the speciﬁc sample
proteins: rabbit polyclonal SIRT1 C-terminal antibody (ab13749,
Abcam); rabbit polyclonal RPS19BP1 (AROS) antibody
(HPA042874, Sigma), rabbit monoclonal acetyl-p53 (Lys382-Ac)
antibody (ab75754, Abcam) and mouse monoclonal a-tubulin
antibody (T5168, Sigma). The protein signals were visualized with
peroxidase-conjugated secondary antibodies (donkey-anti-rabbit,
NA934, and sheep-anti-mouse, NXA931, both from GE Healthcare),
and chemiluminescent substrates (ECL Plus, GE Healthcare;
Immobilon Western Chemiluminescent HRP Substrate, Millipore).
The images were obtained by the use of digital imaging (Image-
Quant, GE Healthcare) or by exposure on ﬁlm (SuperRX, Fujiﬁlm).
2.5. SIRT1 in vitro activity assays
The activity of SIRT1 was measured using Fluor de Lys and
SIRTainty ﬂuorometric assays.
The Fluor de Lys ﬂuorometric assay was modiﬁed from method
described in the Enzo SIRT1 Fluorometric Drug Discovery Kit prod-
uct sheet. Brieﬂy, the reaction was carried out using Fluor de Lys
acetylated SIRT1 substrate (25 lM; BML-KI177, Enzo), NAD+
(100 lM, Sigma) and SIRT1 enzyme (3 U His-SIRT1; BML-SE239,
Enzo). The buffer (BML-KI286, Enzo), substrate, NAD+ and test
compounds (2.5 ll in 50 ll total volume of reaction mixture) were
preincubated for 5 min at room temperature. The reaction was
started by adding the SIRT1 enzyme, and the reaction mixture
was incubated for 30 min at +37 C. After that Fluor de Lys devel-
oper (50 ll; BML-KI176, Enzo) containing nicotinamide (2 mM)
was added and incubation was continued for 45 min at +37 C.
Fluorescence readings were obtained using the Victor 1420 Multi-
label Counter (Perkin Elmer) with excitation wavelength set to
360 nm and emission set to 460 nm. All results were calculated
compared to the appropriate buffer control. SIRT1 activity determi-
nation from mammalian cell lysates was done according to a pre-
viously published Fluor de Lys-based method [32] using 20 lg of
cellular protein/reaction.
The novel commercial SIRTainty Class III HDAC assay (Millipore)
employs nicotinamidase to measure nicotinamide generated upon
the cleavage of NAD+ during sirtuin mediated deacetylation of a
substrate [36]. The assay was carried out according to instructions
given in the user guide, with the exception of using the full-length
His-tagged SIRT1 enzyme (BML-SE239, Enzo) instead of the trun-
cated GST-SIRT1 enzyme which was included in the kit. Reactions
contained test compounds, acetylated peptide substrate (25 lM),
NAD+ (200 lM), nicotinamidase (20 lg/ml) and SIRT1 enzyme
(1.5 U His-SIRT1, BML-SE239, Enzo) in a ﬁnal reaction volume of
25 ll. When testing the SIRT1 activity in HEK293 cell lysates,
5 lg of cellular protein was added, instead of using the recombi-
nant enzymes. The reactions were performed in the presence and
Table 1
Summary of the effects of recombinant AROS proteins on SIRT1 activity.
SIRT1 activity (% of control ± S.E.M.)a
Fluor de Lys assayb Nicotinamidase assayb
Proprietary
substrate
H3K14-Ac
substrate
His-AROS 20 ± 3.5 *** 71 ± 20 88 ± 2.5*
GST-AROS 62 ± 0.3 *** 47 ± 21 56 ± 13*
a Data represent residual SIRT1 activity in % compared to control (100%) ± S.E.M.,
n = 2–3.
b Assay components were used in the following quantities per reaction: Fluor de
Lys assay: SIRT1 3 U, His-AROS 1.7 lg, GST-AROS 0.7 lg; nicotinamidase assay:
SIRT1 1.5 U, His-AROS 1.5 lg, GST-AROS 1.5 lg, GST 0.9 lg.
* Signiﬁcantly different from control (P < 0.05).
*** Signiﬁcantly different from control (P < 0.001).
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All results were calculated compared to the appropriate buffer
control, which in the case of GST-AROS also included the corre-
sponding molar amount of recombinant GST protein.
2.6. Statistical analyses
Statistical differences between groups were tested using
one-way analysis of variance (ANOVA), followed by Tukey’s Multi-
ple comparison test, with P < 0.05 considered as statistically signif-
icant. Data analysis was performed using IBM SPSS Statistics 19.
3. Results and discussion
3.1. Interaction and in vitro activity studies
The physical interaction of AROS with SIRT1 was investigated
by co-immunoprecipitation analyses from transiently transfected
HEK293 cell lysates. A weak interaction between overexpressed
full-length human SIRT1 and AROS was a consistent ﬁnding in
co-immunoprecipitation analyses, but the endogenous proteins
were not detected in the conditions employed (Fig. 1). AROS was
originally reported to interact with the N-terminus of SIRT1 and
to regulate SIRT1 positively [29]. This functional ﬁnding is indi-
rectly supported by a recent report, where overexpression of AROS
was found to increase heat shock factor 1 recruitment to the heat
shock protein 70 (HSP70) promoter, increasing HSP70 transcrip-
tion [33]. The same heat shock pathway is activated by SIRT1 over-
expression [34]. However, in a very recently published study, AROS
failed to activate SIRT1 [35].
In the current study, the effect of recombinant AROS protein on
the activity of SIRT1 was measured using two different in vitro
assays: Fluor de Lys ﬂuorometric assay and a novel commercial
ﬂuorometric sirtuin activity assay (Millipore SIRTainty), which
employs recombinant PNC1 nicotinamidase to measure nicotin-
amide generated upon cleavage of NAD+ during sirtuin-mediated
deacetylation. We ﬁrst started our analyses on how AROS affects
SIRT1 activity by reconstituting the Fluor de Lys assay from the
original publication by Kim et al. [29]. At that time it was surpris-
ing to obtain results which were in conﬂict with the original ﬁnd-
ings, since the only experimental publication on AROS presented it
as a SIRT1 activator. In order to conﬁrm our results, we repeated
the activity measurements with the nicotinamidase-based activity
assay using the commercial SIRTainty assay kit containing a
proprietary acetylated pan-sirtuin substrate. His- and GST-taggedFig. 1. Co-immunoprecipitation of SIRT1 with AROS. SIRT1 and AROS expression
constructs were transfected to HEK293 cells, as indicated. The cell lysates were
subjected to immunoprecipitation with anti-AROS and Western blotting with anti-
SIRT1 (upper panel), or vice versa (lower panel). Input samples are shown on the
left. Blots are representative of seven experiments.versions of AROS were found to inhibit SIRT1 activity or to be with-
out signiﬁcant effect in both assays (Table 1). The degree of inhibi-
tion depended on which preparation of AROS was used (His-tag vs.
GST-tag), and also on the assay method.
The use of bulky ﬂuorophore-containing substrates in Fluor de
Lys activity assays has been reported to cause artifactual results
[37], a problemwhich is avoided by the use of unlabeled substrates
in the nicotinamidase-based assay. It has also been recently found
out that different sirtuin activators exert selective effects on SIRT1
substrates [36,38]. As the nicotinamidase-based assay allows for
testing of various acetylated protein or peptide substrates, we
repeated this assay using two peptide substrates with known se-
quences. Both His- and GST-tagged AROS preparations were signif-
icantly inhibiting SIRT1 when tested using acetylated histone H3
peptide substrate (H3K14-Ac, Table 1). Fluor de Lys acetylated
SIRT1 substrate (BML-KI177, Enzo), based on p53 peptide se-
quence, was also tested in the nicotinamidase-based assay. The
presence of either of the AROS preparations in the reaction resulted
in complete elimination of the signal in this case (data not shown).
The putative interaction site of SIRT1 and AROS was studied uti-
lizing in silico methods. The interaction had been reported to occur
within the region comprising amino acids 114–217 in SIRT1 [29]. A
set of AROS peptides, AR1–5, was designed based on in silicoFig. 2. SIRT1 deletion mutants do not interact with AROS. SIRT1 expression
constructs of full-length SIRT1 (1–747), or deletion mutants containing amino acids
114–747, 124–747, or 134–747 of SIRT1 were transfected to HEK293 cells together
with AROS, as indicated. The cell lysates were subjected to immunoprecipitation
with anti-AROS and Western blotting with anti-SIRT1, or vice versa. Input samples
were also analyzed by Western blotting. Blots are representative of three
experiments.
Fig. 3. AROS does not modulate the activity of SIRT1 in mammalian cells. HEK293
cells were transiently transfected with SIRT1 and AROS expression constructs or
mock-transfected with empty plasmids. After 24 h, the cells were collected and
SIRT1 activity was measured from cell lysates with Fluor de Lys assay. Activity in
mock-transfected lysates was set to 1 (mean ± S.E.M., n = 3). Overexpression of
SIRT1 and AROS was conﬁrmed with Western blotting in each experiment;
representative blots are shown in the lower panels.
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or full-length SIRT1. The sequence alignment of SIRT1 and AROS
(Supplementary Fig. 1) was used to predict the complementary
protein–protein interaction surfaces, and AROS peptides AR1–4
were designed based on these predictions (Supplementary Table 1).
An additional peptide, AR5, was selected based on protein–protein
interaction sites predicted by cons-PPISP and Predict Protein soft-
wares (Supplementary Table 1). Three truncation mutants of SIRT1,
spanning the putative AROS interaction region, were constructed
by targeted deletion mutagenesis. The SIRT1 mutants and the AR
peptides were tested in interaction and activity assays.
The design and construction of SIRT1 truncation mutants did
not provide speciﬁc answer to determine the exact region for theFig. 4. The effects of AROS overexpression and etoposide treatment on p53 acetylation. (A
treatments for 24 h before the start of a 5-h stimulation with etoposide (ETO, 100 lM).
AROS antibodies. (B) Quantitation of acetyl-p53 Western blots; signals were normalizedSIRT1/AROS interaction, since the truncated forms of SIRT1 failed
to co-immunoprecipitate with AROS (Fig. 2). This indicates that
in the conditions employed, amino acids 114–747 of SIRT1 are
not sufﬁcient for interaction with AROS. This also contradicts to
the original ﬁndings that the interaction with AROS is occurring
in the region comprising amino acids 114–217 of SIRT1 [29]. The
previous results for the SIRT1/AROS interacting region were based
on yeast reporter gene assays and GST pull-down experiments
with pure protein preparations and mild washing conditions. Here,
the co-immunoprecipitation conditions were chosen to be identi-
cal to the conditions in which both overexpressed and endogenous
full-length SIRT1 and AROS were previously found to interact with
each other [29]. For this method, cell lysis and washing steps are
done in rather stringent conditions using RIPA buffer. Different
assay conditions (buffers, antibodies, living cells vs. recombinant
protein preparations, yeast cells vs. human cells) can be the reason
for the discrepancies in the observed interactions.
The AROS peptides (AR1–5) were found to exert an inhibitory
effect on SIRT1 activity in two different in vitro assays (Supplemen-
tary Table 2), although a molar excess of the peptides was not able
to block the interaction between SIRT1 and AROS in co-immuno-
precipitation analyses (Supplementary Fig. 2). This can be
explained by the fact that the interaction between SIRT1 and AROS
which was detected in co-immunoprecipitation assays was already
present at the moment of cell lysis, before the addition of peptides
to the lysates. Presumably, the AR peptides did not have high
speciﬁc afﬁnity for SIRT1, which would be necessary for effective
competition of the pre-existing SIRT1/AROS interaction. However,
the weaker interactions of the peptides with SIRT1 were enough
to inhibit its function in the activity assays. The AROS peptides
could also inhibit the deacetylation reaction by competing with
the peptide substrate, preventing the interaction of the substrate
with the substrate binding site of SIRT1.
3.2. Studies using cellular models
To provide further insight into the putative interplay between
AROS and endogenous SIRT1, the activity of SIRT1 was measured
with Fluor de Lys assay from human non-cancerous HEK293 and
ARPE-19 retinal pigment epithelial cell lysates. Transient overex-
pression of AROS did not have a signiﬁcant effect on the endoge-
nous SIRT1 activity in HEK293 cells (Fig. 3) or ARPE-19 cells
(SIRT1 activity 111 ± 6.9% compared to mock-control (100%),
mean ± S.E.M., n = 6). HEK293 cell lysates were also tested in the) The ARPE-19 cells were subjected to transfection with AROS plasmid or to control
Cell lysates were analyzed by Western blotting using acetylated p53, a-tubulin and
with a-tubulin (mean ± S.E.M., n = 3).
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ﬁrmed the non-signiﬁcant effect of AROS overexpression on the
endogenous SIRT1 activity (SIRT1 activity 85 ± 12% compared to
mock-control (100%), mean ± S.E.M., n = 2). In line with these ﬁnd-
ings with endogenous SIRT1, AROS did not affect the activity of
overexpressed full-length SIRT1 in HEK293 cell lysates (Fig. 3).
Tumor suppressor protein p53 is a well-established SIRT1 inter-
action partner and substrate. In response to DNA damage, Lys 382
in p53 is acetylated by histone acetyltransferase p300. Acetylation
of p53 increases its afﬁnity to the target DNA sequence and thus its
transcriptional activity [39]. SIRT1 deacetylates p53 on lysine 382,
inhibiting its activity [4,40]. When etoposide treatment was used
to induce DNA damage in ARPE-19 cells, p53 acetylation was
accordingly increased (Fig. 4). Mock transfection with an empty
vector decreased p53 acetylation compared to control cells, which
had received no treatment at all. Compared to this mock transfec-
tion, overexpression of AROS did not have a signiﬁcant effect on
p53 acetylation (Fig. 4).
The results from in vitro activity assays with ARPE-19 and
HEK293 cell lysates imply that AROS overexpression does not mod-
ulate SIRT1 activity in these two non-cancerous human cell lines.
As AROS has previously been reported to activate the SIRT1-medi-
ated deacetylation of p53 in HCT116 human colon cancer cells and
MCF-7 human breast cancer cells, the effect of AROS on SIRT1 acti-
vation and p53 deacetylation seems to be cell-type dependent and
more prominent in cancer cells. This is supported by the recent re-
port where AROS was found to speciﬁcally promote cancer cell sur-
vival [30]. DBC1, the other endogenous protein which directly
modulates SIRT1 activity, also exerts differential effects on SIRT1-
mediated deacetylation of p53 in different cell types. DBC1 func-
tions as a negative regulator of SIRT1 in A549 lung cancer cells
but not in SNU-182 liver cancer cells [41]. Furthermore, the inter-
action between DBC1 and SIRT1 is lost in many cell types [42].
4. Conclusion
Our results indicate that AROS and SIRT1 are able to physically
interact with each other. Despite using different methods to ana-
lyze the effect of AROS on SIRT1 activity, including the conditions
where the activation had originally been described, we were not
able to conﬁrm AROS as a SIRT1 activator. On the contrary,
in vitro activity assays with recombinant proteins indicated that
AROS acts as an inhibitor of SIRT1. In mammalian cells, AROS over-
expression did not activate SIRT1; this is evidenced both by results
from SIRT1 activity assays and by the minor insigniﬁcant increase
in p53 acetylation. Our results suggest that substrates, biological
context, and even buffer composition can affect the interaction
and the positive or negative effect that AROS exerts on SIRT1. AROS
can also regulate other pathways via its interaction with the ribo-
somal protein S19 or other yet unknown cellular targets. The ﬁnal
role for AROS is not clear and demands further investigation.
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